vs

Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and Metropolitan Bank Holding Corp. (MCB). Click either name above to swap in a different company.

Metropolitan Bank Holding Corp. is the larger business by last-quarter revenue ($88.5M vs $44.9M, roughly 2.0× AbCellera Biologics Inc.). Metropolitan Bank Holding Corp. runs the higher net margin — 35.5% vs -19.9%, a 55.5% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 25.4%). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 14.3%).

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

Sandy Spring Bancorp, Inc. was a bank holding company headquartered in Olney, Maryland and operating in the Washington metropolitan area. In addition to banking services, the company offered commercial and personal lines of insurance, surety bonds, workers compensation insurance, and professional liability insurance protection as well as financial planning, wealth management, and asset management for high-net-worth individuals, businesses, and associations. In April 2025, the company was acqu...

ABCL vs MCB — Head-to-Head

Bigger by revenue
MCB
MCB
2.0× larger
MCB
$88.5M
$44.9M
ABCL
Growing faster (revenue YoY)
ABCL
ABCL
+763.0% gap
ABCL
788.4%
25.4%
MCB
Higher net margin
MCB
MCB
55.5% more per $
MCB
35.5%
-19.9%
ABCL
Faster 2-yr revenue CAGR
ABCL
ABCL
Annualised
ABCL
112.3%
14.3%
MCB

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ABCL
ABCL
MCB
MCB
Revenue
$44.9M
$88.5M
Net Profit
$-8.9M
$31.4M
Gross Margin
Operating Margin
-63.7%
Net Margin
-19.9%
35.5%
Revenue YoY
788.4%
25.4%
Net Profit YoY
73.9%
92.2%
EPS (diluted)
$-0.03
$2.92

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABCL
ABCL
MCB
MCB
Q1 26
$88.5M
Q4 25
$44.9M
$88.4M
Q3 25
$9.0M
$79.8M
Q2 25
$17.1M
$76.3M
Q1 25
$4.2M
$70.6M
Q4 24
$5.0M
$71.0M
Q3 24
$6.5M
$71.5M
Q2 24
$7.3M
$67.7M
Net Profit
ABCL
ABCL
MCB
MCB
Q1 26
$31.4M
Q4 25
$-8.9M
$28.9M
Q3 25
$-57.1M
$7.1M
Q2 25
$-34.7M
$18.8M
Q1 25
$-45.6M
$16.4M
Q4 24
$21.4M
Q3 24
$-51.1M
$12.3M
Q2 24
$-36.9M
$16.8M
Operating Margin
ABCL
ABCL
MCB
MCB
Q1 26
Q4 25
-63.7%
46.6%
Q3 25
-851.8%
12.8%
Q2 25
-290.2%
35.1%
Q1 25
-1479.6%
33.1%
Q4 24
44.1%
Q3 24
-1439.4%
24.6%
Q2 24
-1276.2%
35.3%
Net Margin
ABCL
ABCL
MCB
MCB
Q1 26
35.5%
Q4 25
-19.9%
32.6%
Q3 25
-637.8%
8.9%
Q2 25
-203.3%
24.6%
Q1 25
-1077.2%
23.2%
Q4 24
30.2%
Q3 24
-785.4%
17.2%
Q2 24
-504.3%
24.8%
EPS (diluted)
ABCL
ABCL
MCB
MCB
Q1 26
$2.92
Q4 25
$-0.03
$2.74
Q3 25
$-0.19
$0.67
Q2 25
$-0.12
$1.76
Q1 25
$-0.15
$1.45
Q4 24
$1.89
Q3 24
$-0.17
$1.08
Q2 24
$-0.13
$1.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABCL
ABCL
MCB
MCB
Cash + ST InvestmentsLiquidity on hand
$128.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$966.9M
$948.3M
Total Assets
$1.4B
$8.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABCL
ABCL
MCB
MCB
Q1 26
Q4 25
$128.5M
$393.6M
Q3 25
$83.2M
$385.9M
Q2 25
$92.4M
$152.5M
Q1 25
$159.3M
$196.5M
Q4 24
$156.3M
$200.3M
Q3 24
$126.6M
$318.5M
Q2 24
$148.3M
$244.7M
Stockholders' Equity
ABCL
ABCL
MCB
MCB
Q1 26
$948.3M
Q4 25
$966.9M
$743.1M
Q3 25
$964.0M
$732.0M
Q2 25
$1.0B
$723.0M
Q1 25
$1.0B
$737.8M
Q4 24
$1.1B
$729.8M
Q3 24
$1.1B
$715.2M
Q2 24
$1.1B
$692.4M
Total Assets
ABCL
ABCL
MCB
MCB
Q1 26
$8.8B
Q4 25
$1.4B
$8.3B
Q3 25
$1.4B
$8.2B
Q2 25
$1.4B
$7.9B
Q1 25
$1.3B
$7.6B
Q4 24
$1.4B
$7.3B
Q3 24
$1.4B
$7.4B
Q2 24
$1.4B
$7.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABCL
ABCL
MCB
MCB
Operating Cash FlowLast quarter
$-34.7M
Free Cash FlowOCF − Capex
$-44.6M
FCF MarginFCF / Revenue
-99.4%
Capex IntensityCapex / Revenue
21.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-174.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABCL
ABCL
MCB
MCB
Q1 26
Q4 25
$-34.7M
$88.7M
Q3 25
$-52.6M
$31.8M
Q2 25
$-32.4M
$18.4M
Q1 25
$-11.6M
$7.8M
Q4 24
$-108.6M
$148.5M
Q3 24
$-28.9M
$4.8M
Q2 24
$-30.0M
$35.3M
Free Cash Flow
ABCL
ABCL
MCB
MCB
Q1 26
Q4 25
$-44.6M
Q3 25
$-61.5M
Q2 25
$-45.8M
Q1 25
$-22.2M
Q4 24
$-187.0M
Q3 24
$-47.4M
Q2 24
$-50.1M
FCF Margin
ABCL
ABCL
MCB
MCB
Q1 26
Q4 25
-99.4%
Q3 25
-687.0%
Q2 25
-267.9%
Q1 25
-524.0%
Q4 24
-3702.8%
Q3 24
-728.4%
Q2 24
-683.8%
Capex Intensity
ABCL
ABCL
MCB
MCB
Q1 26
Q4 25
21.9%
Q3 25
99.7%
Q2 25
78.2%
Q1 25
251.1%
Q4 24
1552.7%
Q3 24
284.6%
Q2 24
274.6%
Cash Conversion
ABCL
ABCL
MCB
MCB
Q1 26
Q4 25
3.07×
Q3 25
4.47×
Q2 25
0.98×
Q1 25
0.47×
Q4 24
6.93×
Q3 24
0.39×
Q2 24
2.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons